Disc Medicine Q3 net loss narrows to $59.54 million

Bitget2026/11/05 13:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Disc Medicine’s third-quarter 2026 net loss narrowed year over year to $59.54 million.
Research and development expenses fell 12% year over year to $44.08 million, primarily due to prior-year milestone and manufacturing costs not recurring.
An October public offering raised approximately $485.9 million in net proceeds, extending the cash runway into 2030.
Bitopertin’s pivotal Phase 3 APOLLO trial in erythropoietic protoporphyria met all primary and secondary endpoints.
An NDA resubmission is planned by year-end 2026, with an FDA decision anticipated by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050830PRIMZONEFULLFEED9870783) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Disc Medicine Q3 net loss narrows to $59.54 million

You may also like

Crypto prices